Can AI develop safe and non addictive mind-altering substances, psychedelics or hallucinogens for science and recreation ?
Cast your vote — then read what our editor and the AI models found.
As of 2024, AI has not been used to develop new safe and non-addictive mind-altering substances, as ethical and regulatory barriers, along with the current limitations of AI in drug discovery, make such applications premature. While AI accelerates drug discovery by predicting molecular interactions and optimizing compounds, its role in designing psychedelics or hallucinogens is largely theoretical and constrained by safety, legal, and ethical concerns, particularly regarding psychoactive properties. Most psychedelic research today focuses on repurposing existing compounds (e.g., psilocybin, MDMA) for therapeutic use under strict clinical supervision rather than creating novel substances. Current AI applications prioritize optimizing known drug classes for precision medicine rather than exploring uncharted psychoactive chemical spaces.
— Enriched May 12, 2026 · Source: National Academies of Sciences, Engineering, and Medicine
Suggest a tag
A missing concept on this topic? Suggest it and admin reviews.
Status last checked on May 12, 2026.
Gallery
What the audience thinks
No 67% · Yes 33% · Maybe 0% 3 votesDiscussion
no comments⚖ 1 jury check · most recent 1 day ago
Each row is a separate jury check. Jurors are AI models (identities kept neutral on purpose). Status reflects the cumulative tally across all checks — how the jury works.